BioAlliance Pharma's AMEP biotherapy reduces both tumour growth and tumour angiogenesis

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented preclinical results on its new biotherapy, AMEP™ for advanced and metastatic melanoma at the ESGCT (European Society of Gene and Cell Therapy) in Hannover (November 21 to 25, 2009).

BioAlliance Pharma develops an innovative biotherapy, AMEP™, for the treatment of advanced and metastatic melanomas. This new therapy displays an original mechanism of action by targeting specific receptors involved in the tumour growth and in the tumour angiogenesis.

The data presented at the ESGCT Conference demonstrate that AMEP^TM administration in a human melanoma xenograft model dramatically reduced both tumour growth and tumour angiogenesis, leading to complete regression of the tumour. Amep™ efficacy is significantly superior to that of temozolomide, the standard chemotherapy used in metastatic melanoma treatment.

Regulatory preclinical toxicological studies show that four repeated administrations of AMEP™ at 7-day interval were safe and well tolerated.

Advanced and metastatic melanoma is a late stage skin cancer refractory to most treatments. Thus, there is an unmet medical need for new treatments.